C21 · Pharmaceuticals · China
Approved Class 1 innovative drugs (half year)
China: 38 in January–June 2026.
- 38 Latest · China · January–June 2026
- Irregular Release cadence
- 1 Record · 1 region · 2026
Verified 17 Sep 2026 · 1 publisher · Next period July–December 2026
The figure
One published observation so far. A chart follows as soon as a second period is published.
Approved Class 1 innovative drugs (half year)
China, January–June 2026
Every record
1 record · 1 region · 2026. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| China 1 record | |||
| January–June 2026 | 38 | NHSA · 30 Jun 2026 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: NHSA. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (NHSA); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Total number of Class 1 innovative drugs approved for marketing authorization.
- Measure
- One slice of Drug approvals ( form: count, segment: class 1 innovative ) . Total number of therapeutic drugs granted regulatory marketing approval. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 我国上半年创新药对外授权交易额超千亿美元 | NHSA | — | 1 |
Other slices of drug approvals
- First-in-class drug approvals 9 first in class
- New active substance approvals 6 new active substance
- Innovative drug approvals 5 innovative
- Novel drug approvals 3 novel
- Pediatric medicine approvals 3 pediatric
- Rare disease medicine approvals 3 rare disease
- Approved innovative drugs designated as breakthrough therapies 2 breakthrough therapy
- Common new active substance approvals across major regulatory authorities (multi-year total) 2 cumulative · common across authorities · new active substance
- Domestic first-in-class drug approvals 2 domestic · first in class
- Domestic innovative biological product approvals 2 domestic · innovative biologic
- Domestic innovative chemical drug approvals 2 domestic · innovative chemical
- Domestic innovative drug approvals (half year) 2 domestic · innovative
Frequently asked questions
What is the latest approved Class 1 innovative drugs (half year)?
China: 38 in January–June 2026.
Where does this data come from?
From 1 document published by NHSA. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Approved Class 1 innovative drugs (half year) [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/approved-class-1-innovative-drugs-half-year
"Approved Class 1 innovative drugs (half year)." StatOrigin, 2026, https://statorigin.org/indicators/approved-class-1-innovative-drugs-half-year. Accessed 28 Oct. 2026.
StatOrigin. "Approved Class 1 innovative drugs (half year)." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/approved-class-1-innovative-drugs-half-year.
@misc{statorigin_approved_class_1_innovative_drugs_half_year_2026, title = {Approved Class 1 innovative drugs (half year)}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/approved-class-1-innovative-drugs-half-year}, note = {Data set. Accessed 2026-10-28} }